ロザノリキシズマブ(遺伝子組換え)
Rozanolixizumab (Genetical Recombination)
ロザノリキシズマブは,遺伝子組換えヒト化及びキメラ抗ヒト新生児型Fc受容体(FcRn)モノクローナル抗体であり,H鎖はラット抗FcRn抗体の相補性決定部,ヒトフレームワーク部及びヒトIgG4の定常部からなり,L鎖はラット抗FcRn抗体の可変部及びヒトIgGの定常部からなる.H鎖の225番目のアミノ酸残基はProに置換されている.ロザノリキシズマブは,チャイニーズハムスター卵巣細胞により産生される.ロザノリキシズマブは,444 個のアミノ酸残基からなるH鎖(γ4鎖)2本及び219個のアミノ酸残基からなるL鎖(κ鎖)2本で構成される糖タンパク質(分子量:約148,000)である.
Rozanolixizumab is a recombinant humanized and chimeric anti-human neonatal Fc receptor (FcRn) monoclonal antibody in which the H-chains are composed of complementarity-determining regions derived from rat anti-FcRn monoclonal antibody, human framework regions and a human IgG4 constant regions and the L-chains are composed of variable regions derived from rat anti-FcRn antibody and human IgG constant regions. The amino acid residue at position 225 in the H-chain is substituted by Pro. Rozanolixizumab is produced in Chinese hamster ovary cells. Rozanolixizumab is a glycoprotein (molecular weight: ca. 148,000) composed of 2 H-chains (γ4-chains) consisting of 444 amino acid residues each and 2 L-chains (κ-chains) consisting of 219 amino acid residues each.
[1584645-37-3]
|